Skip to content

US · BRTX · BIOTECHNOLOGY

BioRestorative Therapies, Inc. (BRTX) intrinsic value and stock valuation

$1.05as of 2026-11-21 · Mkt cap 1.89M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

BioRestorative Therapies, Inc. DCF and intrinsic value

InvestorsCraft values BRTX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from BRTX’s statements →

BioRestorative Therapies, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Melville, NY 11747 biorestorative.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$360K+35.1% 5y CAGRd
20112025
Net income
-$-14.24M
20112025
Free cash flow
-$-10.91M
20112025
Total equity
$360K
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$360K$400K$150K$120K$50K
Operating income-$-15.65M-$-11.56M-$-15.22M-$-18.86M-$-26.31M
Net income-$-14.24M-$-8.98M-$-10.42M-$-13.22M-$-44.3M
EPSd-$-1.58M-$-1.16M-$-2.47M-$-3.65M-$-37.23M
Operating cash flow-$-10.79M-$-8.23M-$-6.43M-$-5.91M-$-3.33M
Capital expenditure-$-120K-$-110K-$-170K-$-440K-$-30K
Free cash flow-$-10.91M-$-8.34M-$-6.6M-$-6.35M-$-3.36M
Total assets$4.08M$12.3M$12.6M$16.4M$22.5M
Total debt$0.00$0.00$160K$300K$670K
Net debt-$-1.51M-$-550K-$-720K-$-1.41M-$-20.36M
Total equity$360K$8.53M$10M$10.3M$21.6M
Cash and short-term investments$2.95M$10.7M$11.1M$14.8M$21M
Income statement
20252024202320222021
Revenue$360K$400K$150K$120K$50K
Cost of revenue$20K$30K$0.00$0.00$0.00
Gross profit$340K$370K$150K$120K$50K
Research and development expenses$10.1M$5.35M$4.03M$3.51M$730K
Selling, general and administrative expenses$5.89M$6.58M$11.3M$15.6M$25.6M
Other expenses$0.00$0.00$0.00-$-110K$0.00
Operating expenses$16M$11.9M$15.4M$19M$26.4M
Cost and expenses$16M$12M$15.4M$19M$26.4M
Interest income$270K$620K$550K$10K$0.00
Interest expense$0.00$0.00$0.00$0.00$1.82M
Depreciation and amortization$210K$190K$170K$120K$90K
Ebitda-$-14.03M-$-8.79M-$-14.97M-$-13.1M-$-42.4M
Operating income-$-15.65M-$-11.56M-$-15.22M-$-18.86M-$-26.31M
Total other income/expenses, net$1.41M$2.58M$4.8M$5.64M-$-18M
Income before tax-$-14.24M-$-8.98M-$-10.42M-$-13.22M-$-44.3M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-14.24M-$-8.98M-$-10.42M-$-13.22M-$-44.3M
Weighted average shares outstanding$8.99M$7.76M$4.22M$3.62M$1.19M
Weighted average diluted shares outstanding$8.99M$7.76M$4.22M$3.62M$1.19M
Balance sheet
20252024202320222021
Cash and short-term investments$2.95M$10.7M$11.1M$14.8M$21M
Net receivables$20K$190K$20K$20K$10K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$3.14M$11.1M$11.4M$15.1M$21.5M
Property, plant and equipment, net$360K$360K$510K$500K$400K
Goodwill and intangible assets$530K$620K$710K$800K$590K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$940K$1.14M$1.22M$1.31M$990K
Total assets$4.08M$12.3M$12.6M$16.4M$22.5M
Accounts payable$1.34M$480K$190K$170K$50K
Short-term debt$0.00$0.00$160K$140K$180K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$3.72M$3.75M$2.61M$5.98M$360K
Long-term debt$0.00$0.00$0.00$160K$490K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$160K$490K
Capital lease obligations$0.00$0.00$160K$300K$420K
Total liabilities$3.72M$3.75M$2.61M$6.14M$860K
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-169.92M-$-155.68M-$-146.7M-$-136.28M-$-134.15M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$360K$8.53M$10M$10.3M$21.6M
Total investments$1.44M$10.2M$10.2M$13M$0.00
Total debt$0.00$0.00$160K$300K$670K
Net debt-$-1.51M-$-550K-$-720K-$-1.41M-$-20.36M
Cash flow statement
20252024202320222021
Net income-$-14.24M-$-8.98M-$-10.42M-$-13.22M-$-44.3M
Depreciation and amortization$210K$190K$170K$120K$90K
Stock-based compensation$3.33M$2.81M$7.78M$12.6M$23.1M
Change in working capital$1.31M$30K$520K$10K$320K
Accounts receivable$170K-$-170K-$0.00-$-10K$10K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$840K$290K$20K$120K-$-70K
Net cash provided by operating activities-$-10.79M-$-8.23M-$-6.43M-$-5.91M-$-3.33M
Investments in property, plant and equipment-$-120K-$-110K-$-170K-$-270K-$-30K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$8.9M$510K$3.25M-$-13.4M-$-30K
Common stock issued$3.14M$0.00$2.35M$0.00$21.1M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$2.85M$7.38M$2.35M$0.00$21.3M
Net change in cash$960K-$-340K-$-830K-$-19.31M$18M
Cash at end of period$1.51M$550K$880K$1.71M$21M
Operating cash flow-$-10.79M-$-8.23M-$-6.43M-$-5.91M-$-3.33M
Capital expenditure-$-120K-$-110K-$-170K-$-440K-$-30K
Free cash flow-$-10.91M-$-8.34M-$-6.6M-$-6.35M-$-3.36M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About BioRestorative Therapies, Inc.

        BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.

        CEO
        Lance Alstodt
        Employees
        14
        Beta
        0.74

        Explore

        Frequently asked questions

        What is the intrinsic value of BioRestorative Therapies, Inc. (BRTX)?

        BioRestorative Therapies, Inc. (BRTX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is BRTX undervalued?

        BRTX trades at a price of $1.05 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.